These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6414692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z, Utracka-Hutka B.
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract] [Full Text] [Related]

  • 5. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H, Schnitker J, Fichtner E.
    MMW Munch Med Wochenschr; 1979 Jun 01; 121(22):760-2. PubMed ID: 112422
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD, Munshi N, Einhorn LH, Loehrer PJ.
    Cancer Invest; 1990 Jun 01; 8(2):269. PubMed ID: 2119246
    [No Abstract] [Full Text] [Related]

  • 7. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R.
    Cancer Treat Rep; 1979 Mar 01; 63(3):501-5. PubMed ID: 106965
    [Abstract] [Full Text] [Related]

  • 8. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C, Steiner R, Viollier AF.
    Schweiz Med Wochenschr; 1979 Dec 08; 109(47):1885-7. PubMed ID: 119317
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
    Luce JK, Simons JA.
    Med Pediatr Oncol; 1988 Dec 08; 16(6):372-4. PubMed ID: 3143903
    [Abstract] [Full Text] [Related]

  • 10. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N.
    Recent Results Cancer Res; 1980 Dec 08; 74():270-8. PubMed ID: 6777836
    [Abstract] [Full Text] [Related]

  • 11. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N, Pohl J, Stekar J, Scheef W.
    Eur J Cancer Clin Oncol; 1982 Dec 08; 18(12):1377-87. PubMed ID: 6819957
    [Abstract] [Full Text] [Related]

  • 12. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
    Schnitker J.
    Arzneimittelforschung; 1982 Dec 08; 32(10):1334-8. PubMed ID: 6817761
    [Abstract] [Full Text] [Related]

  • 13. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun 08; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar 08; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 15. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sano T, Suemasu K, Jett JR.
    Jpn J Clin Oncol; 1986 Jun 08; 16(2):153-6. PubMed ID: 3090314
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S.
    Cancer Treat Rev; 1983 Sep 08; 10 Suppl A():93-101. PubMed ID: 6414700
    [Abstract] [Full Text] [Related]

  • 17. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE.
    Oncol Nurs Forum; 1990 Sep 08; 17(2):276. PubMed ID: 2107534
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE, Tessler J.
    Eur J Cancer Clin Oncol; 1983 Feb 08; 19(2):195-201. PubMed ID: 6402369
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Case DC, Anderson J, Ervin TJ, Gottlieb A.
    Med Pediatr Oncol; 1988 Feb 08; 16(3):182-6. PubMed ID: 3132591
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Falkson CI, Falkson HC, Falkson G.
    Invest New Drugs; 1989 Jul 08; 7(2-3):261-7. PubMed ID: 2507474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.